Gilead Sciences

-$1.54 (-2.21%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GILD and other ETFs, options, and stocks.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO
Daniel P. O'Day
Employees
13,600
Headquarters
Foster City, California
Founded
1987

GILD Key Statistics

Market Cap
85.65B
Price-Earnings Ratio
16.67
Dividend Yield
4.07
Average Volume
6.20M
High Today
$69.00
Low Today
$68.01
Open Price
$68.70
Volume
9.62M
52 Week High
$72.31
52 Week Low
$56.56

GILD News

BenzingaJul 30

Understanding Gilead Sciences's Unusual Options Activity - Gilead Sciences

On Friday, shares of Gilead Sciences (NASDAQ:GILD) saw unusual options activity. After the option alert, the stock price moved down to $68.66. Sentiment: BEARI
Simply Wall StJul 30

What Is The Ownership Structure Like For Gilead Sciences, Inc.?

Every investor in Gilead Sciences, Inc. ( ) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and
ReutersJul 29

Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip

Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe

GILD Earnings

$1.11
$1.47
$1.83
$2.19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
$1.73 per share
Actual
$1.87 per share
Replay Earnings Call

More GILD News

CNBCJul 29

Stocks making the biggest moves after hours: Amazon, Pinterest, Gilead & more

Check out the companies making headlines Thursday after the bell: Amazon — Amazon shares fell more than 6% in after-hours trading after the company reported it
MarketWatchJul 29

Gilead Sciences Raises FY Product Sales Forecast

By Kimberly Chin Gilead Sciences Inc. raised the upper end of its full-year product sales target range, as the company saw a strong first half of the year for
BenzingaJul 29

Recap: Gilead Sciences Q2 Earnings

Shares of Gilead Sciences (NASDAQ:GILD) decreased 0.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share inc
MarketWatchJul 29

Sales of Gilead’s COVID-19 drug top $800 million

Gilead Sciences Inc. late Thursday swung to a quarterly profit and reported rising sales thanks to its COVID-19 drug, but a revenue drop from two of its HIV dru
BenzingaJul 27

A Look Into Gilead Sciences Price Over Earnings

Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $68.78, after a 0.1% increase. Moreover, over the past month, the sto
BenzingaJul 26

Gilead Ordered To Pay Attorney Fees In Shareholder Lawsuit

Gilead Sciences Inc. (NYSE: GILD) was ordered to pay about $1.8 million late last week in attorney’s fees and legal expenses to shareholders who sued the compan
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure